5+ hour, 53+ min ago  (227+ words) 29 April 2026 | Wednesday | News Samsung Bioepis Co. , Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and development, today announced that the companies have entered into a Memorandum of Understanding (Mo U) on an…...

12+ hour, 17+ min ago  (287+ words) 28 April 2026 | Tuesday | News Organon stockholders to receive US$ 14. 00 per share in cash The deal values Organon at EV of US$ 11. 75 billion Upon successful consummation of the transaction, Sun Pharma is poised to be: The transaction has been approved by the…...

17+ hour, 4+ min ago  (220+ words) 27 April 2026 | Monday | News In recognition of this critical unmet need, the U. S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology. The Affera mapping…...

23+ hour, 31+ min ago  (105+ words) 28 April 2026 | Tuesday | News The collaboration brings together consulting, device agnostic testing, and drug delivery expertise to help pharmaceutical and biotech companies reduce risk and navigate complexity for combination products, including biologics and GLP1 therapies Under the collaboration, customers will benefit from:…...

1+ day, 26+ min ago  (201+ words) 28 April 2026 | Tuesday | News IMG Pharmaceutical Co. , Ltd. ("IMG Pharma"), a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co. , Ltd. , a Japanese pharmaceutical manufacturer. Founded in…...

1+ day, 34+ min ago  (174+ words) 28 April 2026 | Tuesday | News Ensacove (ensartinib) is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals, Co. Ltd. (Betta). It is indicated for the treatment of adult patients with ALK-positive locally advanced or metastatic NSCLC as detected by…...

1+ day, 16+ hour ago  (189+ words) 27 April 2026 | Monday | News - 13-week U. S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1 R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third…...

2+ day, 8+ min ago  (163+ words) 27 April 2026 | Monday | News Berlin Heals has initiated Phase II of the CMIC-III less invasive FIH study. This next phase will evaluate the therapy in patients with mildly reduced left ventricular ejection fraction (LVEF >40% and Together, these two studies are expected…...

2+ day, 11+ hour ago  (131+ words) 27 April 2026 | Monday | News Ziftomenib was approved by the U. S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R'NPM1-m AML who have no satisfactory alternative treatment options, under the brand name KOMZIFTI. The trial…...

2+ day, 9+ hour ago  (93+ words) 27 April 2026 | Monday | News For Hanchor Bio, the use of intelligence in drug development did not begin with market analysis. It began in molecule design. Hanchor Bio views the use of Bloomberg data and research content as part of a broader…...